Neurotransfer in the direction of company (Q4301691): Difference between revisions
Jump to navigation
Jump to search
(Changed claim: summary (P836): Die Entwicklung neuer Therapien für psychiatrische & neurologische Erkrankungen ist eine der größten Herausforderungen für die Welt der Grundlagen-, Industrie- und klinischen Forschung. Der fehlende Dialog zwischen diesen verschiedenen Akteuren hat jedoch dazu geführt, dass bestimmte Forschungs- u. Entwicklungsbereiche aufgegeben wurden. Neurex, das die neurowissenschaftliche Forschung am Oberrhein in den letzten 2 Jahrzehnten gebündelt hat, sch...) |
(Changed label, description and/or aliases in en, and other parts: Adding English translations) |
||||||||||||||
| label / en | label / en | ||||||||||||||
Neurotransfer in the direction of company | |||||||||||||||
| description / en | description / en | ||||||||||||||
Project Q4301691 in | Project Q4301691 in Germany | ||||||||||||||
| Property / summary | |||||||||||||||
The development of new therapies for psychiatric & neurological diseases is one of the biggest challenges for the world of basic, industrial and clinical research. However, the lack of dialogue between these different actors has led to the abandonment of certain areas of research and development. Neurex, which has bundled neuroscience research on the Upper Rhine over the last 2 decades, proposes to create a project that integrates all actors in the drug development chain. The development of this project requires: 1. a realignment of industrial dynamics towards the identification of therapeutic targets through strong interactions with researchers, 2. training healthcare professionals for innovative therapeutic applications, 3. a retroactive evaluation of the models proposed by researchers by clinicians. The aim of this project is to create knowledge transfers between all members of the chain. In order to achieve this objective, several actions will be carried out, including expert meetings in which the different interest groups (basic research, industrial & clinical research) exchange their expertise. This knowledge transfer is complemented by a partnership with univ. Technology transfer platforms and with biotechs & laboratories on the Upper Rhine. A general public sector should help inform the Rhine population about the functioning of the brain. (English) | |||||||||||||||
| Property / summary: The development of new therapies for psychiatric & neurological diseases is one of the biggest challenges for the world of basic, industrial and clinical research. However, the lack of dialogue between these different actors has led to the abandonment of certain areas of research and development. Neurex, which has bundled neuroscience research on the Upper Rhine over the last 2 decades, proposes to create a project that integrates all actors in the drug development chain. The development of this project requires: 1. a realignment of industrial dynamics towards the identification of therapeutic targets through strong interactions with researchers, 2. training healthcare professionals for innovative therapeutic applications, 3. a retroactive evaluation of the models proposed by researchers by clinicians. The aim of this project is to create knowledge transfers between all members of the chain. In order to achieve this objective, several actions will be carried out, including expert meetings in which the different interest groups (basic research, industrial & clinical research) exchange their expertise. This knowledge transfer is complemented by a partnership with univ. Technology transfer platforms and with biotechs & laboratories on the Upper Rhine. A general public sector should help inform the Rhine population about the functioning of the brain. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The development of new therapies for psychiatric & neurological diseases is one of the biggest challenges for the world of basic, industrial and clinical research. However, the lack of dialogue between these different actors has led to the abandonment of certain areas of research and development. Neurex, which has bundled neuroscience research on the Upper Rhine over the last 2 decades, proposes to create a project that integrates all actors in the drug development chain. The development of this project requires: 1. a realignment of industrial dynamics towards the identification of therapeutic targets through strong interactions with researchers, 2. training healthcare professionals for innovative therapeutic applications, 3. a retroactive evaluation of the models proposed by researchers by clinicians. The aim of this project is to create knowledge transfers between all members of the chain. In order to achieve this objective, several actions will be carried out, including expert meetings in which the different interest groups (basic research, industrial & clinical research) exchange their expertise. This knowledge transfer is complemented by a partnership with univ. Technology transfer platforms and with biotechs & laboratories on the Upper Rhine. A general public sector should help inform the Rhine population about the functioning of the brain. (English) / qualifier | |||||||||||||||
point in time: 21 June 2022
| |||||||||||||||
Revision as of 10:41, 21 June 2022
Project Q4301691 in Germany
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Neurotransfer in the direction of company |
Project Q4301691 in Germany |
Statements
948,269.74 Euro
0 references
1,896,539.48 Euro
0 references
50.0 percent
0 references
1 September 2019
0 references
31 August 2022
0 references
Neurex
0 references
48°31'20.60"N, 7°44'39.55"E
0 references
48°0'29.88"N, 7°51'26.39"E
0 references
48°36'16.38"N, 7°42'42.91"E
0 references
48°33'30.02"N, 7°44'36.46"E
0 references
48°34'21.94"N, 7°45'17.60"E
0 references
47°29'11.80"N, 7°44'0.35"E
0 references
48°0'2.52"N, 7°51'42.73"E
0 references
48°4'15.35"N, 7°21'54.22"E
0 references
47°33'20.48"N, 7°35'5.82"E
0 references
47°33'42.08"N, 7°34'50.02"E
0 references
48°0'21.10"N, 7°50'6.43"E
0 references
48°31'22.91"N, 7°44'38.80"E
0 references
48°35'56.29"N, 7°45'35.86"E
0 references
47°23'15.18"N, 8°2'55.75"E
0 references
48°0'48.49"N, 7°50'27.64"E
0 references
47°33'15.95"N, 7°35'29.44"E
0 references
48°34'50.63"N, 7°45'59.58"E
0 references
48°34'49.73"N, 7°45'51.52"E
0 references
47°34'16.03"N, 7°34'3.36"E
0 references
47°33'29.99"N, 7°34'43.75"E
0 references
47°33'23.94"N, 7°32'43.15"E
0 references
48°34'45.34"N, 7°44'21.52"E
0 references
48°34'38.28"N, 7°44'57.16"E
0 references
Die Entwicklung neuer Therapien für psychiatrische & neurologische Erkrankungen ist eine der größten Herausforderungen für die Welt der Grundlagen-, Industrie- und klinischen Forschung. Der fehlende Dialog zwischen diesen verschiedenen Akteuren hat jedoch dazu geführt, dass bestimmte Forschungs- u. Entwicklungsbereiche aufgegeben wurden. Neurex, das die neurowissenschaftliche Forschung am Oberrhein in den letzten 2 Jahrzehnten gebündelt hat, schlägt vor, ein Projekt zu schaffen, das alle Akteure in der Arzneimittelentwicklungskette integriert. Die Entwicklung dieses Projekts erfordert: 1. eine Neuausrichtung der industriellen Dynamik auf die Identifizierung therapeutischer Ziele durch starke Interaktionen mit Forschern, 2. die Ausbildung von medizinischem Fachpersonal für innovative therapeutische Anwendungen, 3. eine rückwirkende Bewertung der von Forschern vorgeschlagenen Modelle durch Kliniker. Ziel dieses Projekts ist es, Wissenstransfers zw. allen Gliedern der Kette zu schaffen. Zur Erreichung dieses Ziels werden mehrere Maßnahmen durchgeführt, darunter Fachgruppentagungen, in denen die verschiedenen Interessengruppen (Grundlagenforschung, industrielle & klinische Forschung) ihr Fachwissen austauschen. Ergänzt wird dieser Wissenstransfer durch eine Partnerschaft mit univ. Technologietransferplattformen und mit Biotechs & Labors am Oberrhein. Ein allgemeiner öffentlicher Bereich soll dazu beitragen, die Rheinbevölkerung über die Funktionsweisen des Gehirns zu informieren. (German)
0 references
The development of new therapies for psychiatric & neurological diseases is one of the biggest challenges for the world of basic, industrial and clinical research. However, the lack of dialogue between these different actors has led to the abandonment of certain areas of research and development. Neurex, which has bundled neuroscience research on the Upper Rhine over the last 2 decades, proposes to create a project that integrates all actors in the drug development chain. The development of this project requires: 1. a realignment of industrial dynamics towards the identification of therapeutic targets through strong interactions with researchers, 2. training healthcare professionals for innovative therapeutic applications, 3. a retroactive evaluation of the models proposed by researchers by clinicians. The aim of this project is to create knowledge transfers between all members of the chain. In order to achieve this objective, several actions will be carried out, including expert meetings in which the different interest groups (basic research, industrial & clinical research) exchange their expertise. This knowledge transfer is complemented by a partnership with univ. Technology transfer platforms and with biotechs & laboratories on the Upper Rhine. A general public sector should help inform the Rhine population about the functioning of the brain. (English)
21 June 2022
0 references